Omega-3 supplement for depression in people with obesity and low omega-3 levels
Tests an EPA omega-3 supplement against placebo for depression in adults with obesity.
Plain-language title generated from the registry record
Registry title: NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Key facts
- Where
- Taichung, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 54 years old?
Source: NCT07439744, who can take part
Where in Taiwan
- Mind-Body Interface Research Center (MBI Lab & Care)Taichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Science and Technology Council, Taiwan
- Trial code
- NCT07439744
- Record updated
- 27 February 2026
- Original description
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index < 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.Read full original descriptionShow less
Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight/Obese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index < 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
Inclusion: Major depressive disorder; Antidepressant drug-free.
Exclusion: Alcohol or drug abuse/dependence (except for nicotine); Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD); Obsessive-compulsive disorder; Post-traumatic stress disorder; Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement; Schizophrenia; Mania; Active suicidal ideation.